On March 18, 2024, CLS Therapeutics, Inc. announced that it has sent a letter to the Corporate Secretary of Xenetic Biosciences, Inc., for delivery to the board of directors, CLS and CLS LLC took notice of the stockholders? vote, on December 6, 2023 at the 2023 annual meeting of the Company?s stockholders, ?Against? the compensation of the Company?s named executive officers, advised that they have concerns with the Company?s current management, and advocated for change in the Company?s senior management.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4 USD | -2.20% | +3.90% | +15.94% |
Mar. 21 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+15.94% | 6.3M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- XBIO Stock
- News Xenetic Biosciences, Inc.
- CLS Therapeutics Discloses its Views on Xenetic Biosciences